Clinical trials
Phase 3 Diabetes Mellitus, Type 2 trials in Croatia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2006 | 5 |
| 2008 | 6 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Terminated | 4 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 27 |
| Boehringer Ingelheim | 6 |
| Takeda | 5 |
| Eli Lilly and Company | 4 |
| AstraZeneca | 2 |
| Sanofi | 2 |
| Chromaderm, Inc. | 1 |
| GlaxoSmithKline | 1 |
| Intarcia Therapeutics | 1 |
| Resverlogix Corp | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 50 |
| Diabetes Mellitus | 22 |
| Cardiovascular Diseases | 2 |
| Glucose Intolerance | 2 |
| Glucose Metabolism Disorders | 2 |
| Hyperglycemia | 2 |
| Obesity | 2 |
| Overweight | 2 |
| Acute Coronary Syndrome | 1 |
| Coronary Artery Disease | 1 |
Trials
Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.